Celia C LaBranche,Andrew T McGuire,Matthew D Gray,Shay Behrens,Peter D Kwong,Xuejun Chen,Tongqing Zhou,Quentin J Sattentau,James Peacock,Amanda Eaton,Kelli Greene,Hongmei Gao,Haili Tang,Lautaro G Perez,Xuejun Chen,Kevin O Saunders,Peter D Kwong,John R Mascola,Barton F Haynes,Leonidas Stamatatos,David C Montefiori,Celia C. LaBranche,Andrew T. McGuire,Matthew D. Gray,Quentin J. Sattentau,Lautaro G. Perez,Kevin O. Saunders,John R. Mascola,Barton F. Haynes,David C. Montefiori

Abstract:Broadly neutralizing antibody (bnAb) induction is a high priority for effective HIV-1 vaccination. VRC01-class bnAbs that target the CD4 binding site (CD4bs) of trimeric HIV-1 envelope (Env) glycoprotein spikes are particularly attractive to elicit because of their extraordinary breadth and potency of neutralization in vitro and their ability to protect against infection in animal models. Glycans bordering the CD4bs impede the binding of germline-reverted forms of VRC01-class bnAbs and therefore constitute a barrier to early events in initiating the correct antibody lineages. Deleting a subset of these glycans permits Env antigen binding but not virus neutralization, suggesting that additional barriers impede germline-reverted VRC01-class antibody binding to functional Env trimers. We investigated the requirements for functional Env trimer engagement of VRC01-class naïve B cell receptors by using virus neutralization and germline-reverted antibodies as surrogates for the interaction. Targeted deletion of a subset of N-glycans bordering the CD4bs, combined with Man5 enrichment of remaining N-linked glycans that are otherwise processed into larger complex-type glycans, rendered HIV-1 426c Env-pseudotyped virus (subtype C, transmitted/founder) highly susceptible to neutralization by near germline forms of VRC01-class bnAbs. Neither glycan modification alone rendered the virus susceptible to neutralization. The potency of neutralization in some cases rivaled the potency of mature VRC01 against wildtype viruses. Neutralization by the germline-reverted antibodies was abrogated by the known VRC01 resistance mutation, D279K. These findings improve our understanding of the restrictions imposed by glycans in eliciting VRC01-class bnAbs and enable a neutralization-based strategy to monitor vaccine-elicited early precursors of this class of bnAbs.

A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodies

Staged Induction of HIV-1 Glycan–dependent Broadly Neutralizing Antibodies

Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope

Potent and Broad HIV-neutralizing Antibodies in Memory B Cells and Plasma

Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design

HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen

Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo

Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies

Characterization of a monoclonal antibody that binds to both gp120 and gp41

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Augmenting Neutralization Breadth Against Diverse HIV-1 by Increasing the Ab-Ag Interface on V2

Recognition Of Synthetic Glycopeptides By Hiv-1 Broadly Neutralizing Antibodies And Their Unmutated Ancestors

Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1

E108 Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth

Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies